|
by Németh, Bertalan, Csanádi, Marcell, Inotai, András, Ameyaw, David
Published 2022
“... on financing high-priced medicines. The market access strategies for innovative medicines in LICs usually...”Published 2022
World Health Organization
|
by Lemmens, Trudo, Ghimire, Kanksha Mahadevia, Perehudoff, Katrina, Persaud, Navindra
Published 2022
“...High prices can significantly restrict access to medicines and may have an impact on health equity...”Published 2022
World Health Organization
|
by Perehudoff, Katrina, Mara, Kaitlin, Hoen, Ellen F. M. 't
Published 2021
“... of pharmaceutical markets in two main areas: (i) the price transparency of medicines, vaccines and health products...”Published 2021
HEN, Health Evidence Network, WHO Regional Office for Europe
|
by Panteli, Dimitra, Edwards, Suzanne
Published 2018
Published 2018
World Health Organization, Regional Office for Europe
|
Will population ageing spell the end of the welfare state? : a review of evidence and policy options
by Cylus, Jonathan, Figueras, Josep, Normand, Charles E. M.
Published 2019
“... effect on health expenditure forecasts, compared to traditional cost drivers such as price growth...”Published 2019
World Health Organization, Regional Office for Europe
|
Will population ageing spell the end of the welfare state? : a review of evidence and policy options
by Cylus, Jonathan, Figueras, Josep, Normand, Charles E. M.
Published 2019
“... effect on health expenditure forecasts, compared to traditional cost drivers such as price growth...”Published 2019
World Health Organization, Regional Office for Europe
|
by Moon, Suerie, Vieira, Marcela, Alonso Ruiz, Adrián, Navarro, Danielle
Published 2022
“...Public concern has been increasing about the high prices of novel medicines, limits on availability...”Published 2022
World Health Organization